TriangleNCT01318317 · OUTCOME
Progression-free Survival at 1 Year
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 1 year
What was measured
Estimated using the Kaplan-Meier methods. Progression is defined using the revised IWG response criteria, as any new lesion or increase by ≥50% of previously involved sites from nadir.
Groups in this outcome
Treatment (Cellular Adoptive Immunotherapy Following PBSCT)
Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with Granulocyte-Colony Stimulating Factor (G-CSF) and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplantation. Patients receive standard myeloablative conditioning followed by autologous Peripheral Blood Stem Cell Transplant (PBSCT). Patients then undergo infusion of ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) on day 2 or 3 after transplantation. peripheral blood stem cell transplantation (PBSCT): Undergo autologous PBSCT filgrastim: Given IV polymerase chain reaction: Correlative studies rituximab: Given IV genetically engineered lymphocyte therapy: Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) laboratory biomarker analysis: Correlative studies plerixafor: Given IV autologous hematopoietic stem cell transplantation: Undergo autologous PBSCT
| Group | Source count |
|---|---|
| Treatment (Cellular Adoptive Immunotherapy Following PBSCT) | 8 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Cellular Adoptive Immunotherapy Following PBSCT) | 50 | Not reported | 16 | 84 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 16
- upper Limit
- 84
- value
- 50
- denoms
- counts
- group Id
- OG000
- value
- 8
- units
- Participants
- description
- Estimated using the Kaplan-Meier methods. Progression is defined using the revised IWG response criteria, as any new lesion or increase by ≥50% of previously involved sites from nadir.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with Granulocyte-Colony Stimulating Factor (G-CSF) and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplantation. Patients receive standard myeloablative conditioning followed by autologous Peripheral Blood Stem Cell Transplant (PBSCT). Patients then undergo infusion of ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) on day 2 or 3 after transplantation. peripheral blood stem cell transplantation (PBSCT): Undergo autologous PBSCT filgrastim: Given IV polymerase chain reaction: Correlative studies rituximab: Given IV genetically engineered lymphocyte therapy: Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) laboratory biomarker analysis: Correlative studies plerixafor: Given IV autologous hematopoietic stem cell transplantation: Undergo autologous PBSCT
- id
- OG000
- title
- Treatment (Cellular Adoptive Immunotherapy Following PBSCT)
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Up to 1 year
- title
- Progression-free Survival at 1 Year
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice